Home
GRI
GRI News

Latest GRI Bio Inc. (GRI) News on June 29, 2025

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire

3 days ago

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

GlobeNewswire

a month ago

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

a month ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GlobeNewswire

a month ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GlobeNewswire

a month ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire

2 months ago

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire

2 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GlobeNewswire

2 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

GlobeNewswire

3 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

GlobeNewswire

3 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire

3 months ago

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GlobeNewswire

3 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GlobeNewswire

3 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire

3 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

GlobeNewswire

4 months ago

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

GRI Bio Announces Reverse Stock Split

GlobeNewswire

4 months ago

GRI Bio Announces Reverse Stock Split

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire

4 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GlobeNewswire

6 months ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

7 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire

7 months ago

GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GlobeNewswire

7 months ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GlobeNewswire

8 months ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

GlobeNewswire

8 months ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire

8 months ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GlobeNewswire

9 months ago

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GlobeNewswire

9 months ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GlobeNewswire

9 months ago

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GlobeNewswire

9 months ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio Participates in Virtual Investor KOL Connect Segment

GlobeNewswire

9 months ago

GRI Bio Participates in Virtual Investor KOL Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

10 months ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

GlobeNewswire

10 months ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

10 months ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GlobeNewswire

a year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GlobeNewswire

a year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

GlobeNewswire

a year ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GlobeNewswire

a year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

GlobeNewswire

a year ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

GlobeNewswire

a year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GlobeNewswire

a year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Announces Pricing of $4 Million Public Offering

GlobeNewswire

a year ago

GRI Bio Announces Pricing of $4 Million Public Offering

GRI Bio Announces Reverse Stock Split

GlobeNewswire

a year ago

GRI Bio Announces Reverse Stock Split

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

GlobeNewswire

a year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

GlobeNewswire

a year ago

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GlobeNewswire

a year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GlobeNewswire

a year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire

a year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

GlobeNewswire

a year ago

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GlobeNewswire

a year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GlobeNewswire

a year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GlobeNewswire

a year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GlobeNewswire

a year ago

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GlobeNewswire

a year ago

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GlobeNewswire

a year ago

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GlobeNewswire

a year ago

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GRI Bio Announces Pricing of $5.5 Million Public Offering

GlobeNewswire

a year ago

GRI Bio Announces Pricing of $5.5 Million Public Offering

BTC Digital Ltd. Announces Launch of Ethereum (ETH) Staking Services

PR Newswire

a year ago

BTC Digital Ltd. Announces Launch of Ethereum (ETH) Staking Services

SRM Entertainment Showcases New Products at the 2024 Las Vegas Winter Market Gift Show

GlobeNewswire

a year ago

SRM Entertainment Showcases New Products at the 2024 Las Vegas Winter Market Gift Show

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

ACCESSWIRE

a year ago

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

GRI Bio Announces Reverse Stock Split

GlobeNewswire

a year ago

GRI Bio Announces Reverse Stock Split

Foresight: Rail Vision's Main Line System Secures EU Railway Standards Approval and Certifications

GlobeNewswire

a year ago

Foresight: Rail Vision's Main Line System Secures EU Railway Standards Approval and Certifications

Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics

ACCESSWIRE

a year ago

Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics

Nuvve Wins $16M Project for Fresno Economic Opportunities Commission's 50-Shuttle Fleet

PR Newswire

a year ago

Nuvve Wins $16M Project for Fresno Economic Opportunities Commission's 50-Shuttle Fleet

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

Business Wire

a year ago

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

ACCESSWIRE

a year ago

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

Laser Photonics Receives Order from Oil City Iron Works for Its CleanTech Laser Cleaning System

ACCESSWIRE

a year ago

Laser Photonics Receives Order from Oil City Iron Works for Its CleanTech Laser Cleaning System

CENTOGENE Announces Preliminary Full Year 2023 Revenue

GlobeNewswire

a year ago

CENTOGENE Announces Preliminary Full Year 2023 Revenue

ClearSign Technologies Corporation Announces Successful Start Up of Multi-Burner Heater in California Project

PR Newswire

a year ago

ClearSign Technologies Corporation Announces Successful Start Up of Multi-Burner Heater in California Project

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Horizon Aircraft Completes Business Combination with Pono Capital Three, Inc. to Become a Publicly Traded Company

GlobeNewswire

a year ago

Horizon Aircraft Completes Business Combination with Pono Capital Three, Inc. to Become a Publicly Traded Company

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

InvestorPlace

a year ago

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

Business Wire

a year ago

Xos and ElectraMeccanica Announce Proposed Combination to Accelerate Xos’ Leadership Position in Manufacturing Commercial Electric Vehicles for Major U.S. Fleet Customers

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

ACCESSWIRE

a year ago

Nocera Inc. Announces Senior Leadership Change

Advent Technologies Secures Funding from Danish Energy Technology Development and Demonstration Program for Innovative R&D Project

Business Wire

a year ago

Advent Technologies Secures Funding from Danish Energy Technology Development and Demonstration Program for Innovative R&D Project

GlobeNewswire

a year ago

AirNet Announces Receipt of Deficiency Letter from Nasdaq

GlobeNewswire

a year ago

Aeries Technology to Participate at the 26th Annual ICR Conference

3 EV Stocks to Sell in January Before They Crash and Burn

InvestorPlace

a year ago

3 EV Stocks to Sell in January Before They Crash and Burn

LED Lighting and EV Charging Solutions Provider Orion to Participate in Virtual Sidoti Microcap Conf. Weds & Thurs, Jan 17-18; Presentation Jan 18th at 10am ET

GlobeNewswire

a year ago

LED Lighting and EV Charging Solutions Provider Orion to Participate in Virtual Sidoti Microcap Conf. Weds & Thurs, Jan 17-18; Presentation Jan 18th at 10am ET

Harte Hanks Extends Line of Credit with Texas Capital Bank

ACCESSWIRE

a year ago

Harte Hanks Extends Line of Credit with Texas Capital Bank

Steakholder Foods crafts 3-D printed eel

Food Dive

a year ago

Steakholder Foods crafts 3-D printed eel

The Ed Mylett Show Joins the Cumulus Podcast Network

GlobeNewswire

a year ago

The Ed Mylett Show Joins the Cumulus Podcast Network

Are Investors Undervaluing Ardmore Shipping (ASC) Right Now?

Zacks

a year ago

Are Investors Undervaluing Ardmore Shipping (ASC) Right Now?

Feasibility Report Confirms Regulatory Path in UAE for Steakholder Foods® 3D-Printed, Plant-Based Products

PR Newswire

a year ago

Feasibility Report Confirms Regulatory Path in UAE for Steakholder Foods® 3D-Printed, Plant-Based Products

Greater Boston-Based Harte Hanks Continues Growth Phase with Addition of Global Advertising Executive Elizabeth Ross to Board of Directors

ACCESSWIRE

a year ago

Greater Boston-Based Harte Hanks Continues Growth Phase with Addition of Global Advertising Executive Elizabeth Ross to Board of Directors

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

PR Newswire

a year ago

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

PINTEC Announces Appointment of New Chief Financial Officer

PR Newswire

a year ago

PINTEC Announces Appointment of New Chief Financial Officer

Estimating The Intrinsic Value Of AirNet Technology Inc. (NASDAQ:ANTE)

Simply Wall St.

2 years ago

Estimating The Intrinsic Value Of AirNet Technology Inc. (NASDAQ:ANTE)

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

Simply Wall St.

2 years ago

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

BiggerPockets Podcast Network Moves to Cumulus

GlobeNewswire

2 years ago

BiggerPockets Podcast Network Moves to Cumulus

Former Director of Security of the Israeli Defense Establishment Nir Ben Moshe Joining ParaZero

GlobeNewswire

2 years ago

Former Director of Security of the Israeli Defense Establishment Nir Ben Moshe Joining ParaZero

Clene Provides Update on ALS Clinical Development Meeting With FDA

GlobeNewswire

2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Medigus: ParaZero Successfully Completed its Drone Safety Project with a Fortune 500 Leading Automotive Manufacturer

GlobeNewswire

2 years ago

Medigus: ParaZero Successfully Completed its Drone Safety Project with a Fortune 500 Leading Automotive Manufacturer

How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

NewMediaWire

2 years ago

How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

CENTOGENE Announces Voting Results of Extraordinary General Meeting

GlobeNewswire

2 years ago

CENTOGENE Announces Voting Results of Extraordinary General Meeting

HUB Announces Reverse Share Split

GlobeNewswire

2 years ago

HUB Announces Reverse Share Split

News Direct

2 years ago

GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

GlobeNewswire

2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire

2 years ago

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Share on Social Networks: